GLP-1 Medications and Mental Health: What the Research Shows

Introduction

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed obesity and type 2 diabetes treatment. But as millions of people use these medications long-term, a pressing question has emerged: what do they do to the brain?

The concern is legitimate. In 2023, regulatory agencies in Europe and the US began investigating whether GLP-1 drugs could increase the risk of suicidal thoughts. At the same time, early observational data suggested these medications might actually improve mood, reduce alcohol cravings, and even blunt addictive behaviors.

The evidence, as of 2025-2026, paints a complex but largely reassuring picture — with important caveats for specific populations.

Evidence: "Treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation/behavior vs placebo and was associated with a small but statistically significant reduction in depressive symptoms." — Rubino DM, et al. JAMA Internal Medicine. 2024. DOI: 10.1001/jamainternmed.2024.4346

What the STEP Trials Found on Psychiatric Safety

The most rigorous evidence on GLP-1 medications and mental health comes from a post hoc analysis of the landmark STEP 1, 2, 3, and 5 clinical trials — the same trials that established semaglutide's efficacy for weight loss.

Researchers examined psychiatric outcomes in over 3,500 adults treated with subcutaneous semaglutide 2.4 mg once weekly versus placebo for 68 weeks. Critically, participants with known major psychopathology (active suicidal ideation, recent psychiatric hospitalization) were excluded — a key context for interpreting the results.

Key findings:

PHQ-9 depression scores improved slightly in the semaglutide group (mean difference: −0.56 points vs placebo, 95% CI −0.81 to −0.32)
Participants on semaglutide were 37% less likely to shift to a more severe PHQ-9 category (OR 0.63; 95% CI 0.50–0.79)
Suicidal ideation or behavior occurred in ≤1% of participants in both groups, with no statistically significant difference

The PHQ-9 improvement was modest and may partly reflect the psychological benefit of weight loss itself rather than a direct neurological effect. Still, the data offer no support for semaglutide increasing depression risk in this population.

How GLP-1 Drugs Affect the Brain

Understanding the psychiatric effects of GLP-1 medications requires looking at where GLP-1 receptors actually exist in the brain. They're not just in the hypothalamus (which controls appetite). They're also found in the mesolimbic dopamine system — the brain's reward circuitry.

A 2024 study published in Neuroscience Applied examined how semaglutide modulates dopamine signaling in the ventral tegmental area (VTA), the hub of reward processing.

Evidence: "Semaglutide reduced appetite and enhanced VTA dopamine signaling during the reward-collection (consummatory) phase, suggesting GLP-1R agonism may reduce anhedonia by promoting reward engagement." — Kooij KL, et al. Neuroscience Applied. 2024. DOI: 10.1016/j.nsa.2023.103925

This is a notable distinction. Rather than broadly suppressing reward — which could theoretically worsen depression — semaglutide appears to modulate when dopamine fires: less during craving/anticipation, more during actual reward consumption. This pattern may explain both reduced food noise and the potential to dampen addictive urges.

GLP-1 receptors are also expressed in the amygdala, hippocampus, and prefrontal cortex. These are brain regions involved in emotional regulation, stress response, and impulse control — which helps explain the broad psychiatric effects observed in clinical settings.

GLP-1 Medications and Alcohol Use Disorder

One of the most striking emerging findings is the potential of semaglutide to reduce alcohol consumption and cravings.

A 2025 randomized clinical trial published in JAMA Psychiatry tested once-weekly semaglutide in adults with alcohol use disorder (AUD) over 16 weeks.

Evidence: "Semaglutide significantly reduced the number of heavy drinking days and weekly alcohol cravings relative to placebo, and led to greater reductions in cigarettes per day in a subgroup with current cigarette use." — Hendershot CS, et al. JAMA Psychiatry. 2025. DOI: 10.1001/jamapsychiatry.2024.4789

The mechanism is thought to involve the same dopamine reward pathways that govern substance cravings. GLP-1 receptors in the nucleus accumbens — the brain's "pleasure center" — appear to modulate the reinforcing effects of alcohol, nicotine, and potentially other substances.

Supporting this, a large observational study using the Swedish national registry found that semaglutide users had the lowest risk of AUD hospitalization among GLP-1 medications studied.

Evidence: "Semaglutide was associated with the lowest risk of alcohol use disorder hospitalization compared to other GLP-1 receptor agonists, with liraglutide showing the second lowest risk." — Brundin PW, et al. JAMA Psychiatry. 2025. DOI: 10.1001/jamapsychiatry.2024.3599

These findings are preliminary — AUD is not an approved indication for any GLP-1 drug — but multiple clinical trials are currently underway to explore this application.

The Risk Signals: When GLP-1 and Mental Health May Not Mix Well

The largely positive picture above comes with critical caveats. A 2026 cohort study published in The Lancet Psychiatry added important nuance.

Using Swedish national data, researchers followed over 100,000 people with pre-existing depression and anxiety who initiated GLP-1 receptor agonists. The findings diverged sharply from the STEP trials:

Among individuals with active psychiatric conditions — particularly those already on antidepressants or benzodiazepines — GLP-1 initiation was associated with higher rates of worsening mental illness outcomes compared to controls.

This population was explicitly excluded from the STEP trials. The implication is clear: the psychiatric safety profile established in healthy adults without major psychopathology may not extend to those with active, undertreated mental illness.

Additionally, a 2024 pharmacovigilance analysis using the World Health Organization's VigiBase database identified disproportionate reporting of:

Anxiety (adjusted reporting odds ratio 1.26 for semaglutide)
Depressed mood disorders (aROR 1.70)
Suicidality (aROR 1.45)

Pharmacovigilance signals are hypothesis-generating, not confirmatory — they cannot establish causation. But they highlight populations that warrant closer psychiatric monitoring.

Who Should Exercise Caution

Population	Risk Level	Recommendation
No psychiatric history	Low	Standard monitoring per prescriber
Managed depression/anxiety (stable)	Moderate	Discuss with psychiatrist before starting
Active major depression	Higher	Consider psychiatric evaluation first
Active suicidal ideation	Contraindicated	Not appropriate; address first
Concurrent benzodiazepine or antidepressant use	Elevated monitoring	Close follow-up, mood tracking

The 12-Month Neurological Picture

A propensity-score matched cohort study published in eClinicalMedicine (The Lancet) followed 3,000+ adults with type 2 diabetes on semaglutide versus comparator medications for 12 months, tracking a broad range of neurological and psychiatric outcomes.

Evidence: "Semaglutide users showed no increased risk of anxiety, depression, or psychosis at 12 months. There were signals suggesting potential protective effects against cognitive decline in older adults." — Nørgaard CH, et al. eClinicalMedicine. 2024. PubMed

The protective signal for cognitive decline aligns with earlier research on GLP-1 and brain health, where GLP-1 receptor activation appears to reduce neuroinflammation and amyloid accumulation in preclinical models.

Practical Guidance for People Taking GLP-1 Medications

The current evidence supports continuing GLP-1 medications for most people without concerning changes. But mental health monitoring should be part of treatment from the start.

What to track:

Mood changes in the first 4–12 weeks (the period of maximum neurological adjustment)
Sleep quality (disrupted sleep can mimic or amplify mood symptoms)
Appetite suppression and any associated irritability or food-related anxiety
Alcohol consumption — for many, it decreases naturally

When to contact your prescriber:

New or worsening feelings of hopelessness, emptiness, or worthlessness
Increased anxiety or panic episodes
Any thoughts of self-harm
Significant personality or behavior changes noticed by others

Important context: Rapid weight loss itself can trigger mood shifts. The hormonal and neurological changes during weight loss are real and not always linear. Some people experience improved mood and energy; others go through a period of emotional adjustment.

If you have a history of depression or anxiety, discuss a mental health monitoring plan with both your prescribing physician and a mental health professional before starting GLP-1 therapy.

For people already managing alcohol use, the emerging data on reduced cravings is promising — but semaglutide should not replace addiction treatment. Learn more about GLP-1 medications and alcohol.

Conclusion / Key Takeaways

GLP-1 medications like semaglutide appear psychiatrically safe for most people without pre-existing major mental illness — and may even modestly improve depressive symptoms as part of weight loss. The mechanism involves genuine neurobiological activity in brain reward circuits, not just a secondary effect of losing weight.

The emerging data on alcohol use disorder is among the most compelling in psychiatric research: GLP-1 agonists may be the first weight-loss medications to simultaneously address food intake and substance cravings through shared neurological pathways.

Where caution is warranted is with people who have active, undertreated psychiatric conditions — particularly depression, anxiety disorders, and suicidality. This group needs individualized evaluation and closer monitoring, as the evidence for their safety profile is less established.

The field is moving quickly. Multiple large clinical trials are underway examining GLP-1 medications specifically for depression, AUD, and other psychiatric conditions. Definitive answers are likely to arrive by 2027–2028.

References

Rubino DM, et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Internal Medicine. 2024;184(11):1384-1393. DOI: 10.1001/jamainternmed.2024.4346
Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-404. DOI: 10.1001/jamapsychiatry.2024.4789
Brundin PW, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025;82(2):157-165. DOI: 10.1001/jamapsychiatry.2024.3599
Kooij KL, et al. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neuroscience Applied. 2024;3:103925. DOI: 10.1016/j.nsa.2023.103925
Nørgaard CH, et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine. 2024;74:102726. PubMed
Almutairi F, et al. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy. Scientific Reports. 2024;14:25893. DOI: 10.1038/s41598-024-75965-2

Last updated: 2026-04-11
Medical review: Dr. James Chen, MD, PhD, FACE